GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Checkmate Pharmaceuticals Inc (NAS:CMPI) » Definitions » Price-to-Free-Cash-Flow

Checkmate Pharmaceuticals (Checkmate Pharmaceuticals) Price-to-Free-Cash-Flow : N/A (As of Jun. 06, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Checkmate Pharmaceuticals Price-to-Free-Cash-Flow?

As of today (2024-06-06), Checkmate Pharmaceuticals's share price is $10.50. Checkmate Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2022 was $-2.32. Hence, Checkmate Pharmaceuticals's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Checkmate Pharmaceuticals's Price-to-Free-Cash-Flow or its related term are showing as below:

CMPI's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.425
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Checkmate Pharmaceuticals's Free Cash Flow per Share for the three months ended in Mar. 2022 was $-0.49. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-2.32.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -0.50% per year.

During the past 4 years, Checkmate Pharmaceuticals's highest 3-Year average Free Cash Flow per Share Growth Rate was -0.50% per year. The lowest was -0.50% per year. And the median was -0.50% per year.


Checkmate Pharmaceuticals Price-to-Free-Cash-Flow Historical Data

The historical data trend for Checkmate Pharmaceuticals's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Checkmate Pharmaceuticals Price-to-Free-Cash-Flow Chart

Checkmate Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21
Price-to-Free-Cash-Flow
- - - -

Checkmate Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Checkmate Pharmaceuticals's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Checkmate Pharmaceuticals's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Checkmate Pharmaceuticals's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Checkmate Pharmaceuticals's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Checkmate Pharmaceuticals's Price-to-Free-Cash-Flow falls into.



Checkmate Pharmaceuticals Price-to-Free-Cash-Flow Calculation

Checkmate Pharmaceuticals's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=10.50/-2.315
=N/A

Checkmate Pharmaceuticals's Share Price of today is $10.50.
Checkmate Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.32.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Checkmate Pharmaceuticals  (NAS:CMPI) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Checkmate Pharmaceuticals Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Checkmate Pharmaceuticals's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Checkmate Pharmaceuticals (Checkmate Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Checkmate Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing its proprietary technology to harness the power of the immune system to combat cancer.
Executives
Venbio Global Strategic Fund Ii L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Alan Bash director, officer: Chief Executive Officer C/O CHECKMATE PAHRMACEUTICALS, INC. 245 MAIN STREET 2ND FLOOR CAMBRIDGE MA 02142
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Jon Marc Wigginton director 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Joy Yan director 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Arthur M Krieg director, officer: Chief Scientific Officer C/O CHECKMATE PHARMACEUTICALS, INC., 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142
Robert Dolski officer: Chief Financial Officer C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Barry Labinger director, officer: President and CEO C/O CHECKMATE PHARMACEUTICALS, INC., 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142
Peter Colabuono director C/O DECHENG CAPITAL 3000 SAND HILL ROAD, BUILDING 2, STE 110 MENLO PARK CA 94025
Oren Isacoff director C/O LONGITUDE CAPITAL 2740 SAND HILL ROAD, 2ND FLOOR MENLO PARK CA 94025
Karen Brennan officer: Chief Operating Officer C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Kleem Chaudhary officer: Chief Business Officer C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Venbio Global Strategic Gp Ii, L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Venbio Global Strategic Gp Ii, Ltd. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Nilesh Kumar director C/O MILESTONE PHARMACEUTICALS, INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTR?AL A8 H4M 2X6

Checkmate Pharmaceuticals (Checkmate Pharmaceuticals) Headlines

From GuruFocus

Top 5 2nd Quarter Trades of venBio Partners LLC

By GuruFocus Research GuruFocus Editor 08-16-2022